Treats migraine with or without aura. ANDA 202803, held by Sun Pharm. Naproxen Sodium; Sumatriptan Succinate.
As of Nov 16, 2026, ANDA 202803 (Sumatriptan And Naproxen Sodium), held by Sun Pharm, was first approved by FDA on Jul 20, 2018, with 4 approved supplements and 0 published complete response letters.
Sumatriptan and naproxen sodium tablets are indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan and naproxen sodium tablets, reconsider the diagnosis of migraine before sumatriptan and naproxen sodium tablets are administered to treat any subsequent attacks. Sumatriptan and naproxen sodium tablets are not indicated for the prevention of migraine attacks.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sumatriptan And Naproxen Sodium500MG;EQ 85MG BASE · tablet;oral | Naproxen Sodium; Sumatriptan Succinate | Rx |
| Nov 10, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 10, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 10, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 4, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 20, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters